Milestone Pharmaceuticals Inc. (MIST)
NMS · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 1.5M | 238K |
| Gross Profit | 224K | |||
| Operating Income | -12.5M | -11.8M | -17.3M | -23.7M |
| Net Income | -13.0M | -11.9M | -17.4M | -26.1M |
| Diluted EPS | $-0.20 | $-0.12 | $nan | $-0.20 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 5.0M | 1.0M | 0.00 | 1.5M |
| Operating Income | -59.6M | -61.1M | -42.1M | -62.1M |
| Net Income | -58.4M | -59.7M | -41.5M | -63.1M |
| Diluted EPS | $-1.38 | $-1.39 | $-0.67 | $nan |